



## SUPPLEMENTARY DATA

**Supplementary Figure 1.** Proportion of patients achieving HbA<sub>1c</sub> targets of <7.0%.



**Supplementary Figure 2.** Mean nine-point SMPG at baseline and at 26 weeks for IDegAsp and BIAsp 30 BID.



\*Indicates significant difference.

## SUPPLEMENTARY DATA

**Supplementary Table 1.** Breakdown of OADs in patients receiving >1 OAD at baseline.

Characteristic	IDegAsp (n=224)	BIAsp 30 (n=222)
Receiving 2 OADs, n (%)	40 (17.9)	33 (14.9)
Alpha-glucosidase inhibitor + Biguanide	2 (0.9)	3 (1.4)
Alpha-glucosidase inhibitor + Thiazolidinedione	-	1 (0.5)
Biguanide + DPP-4 inhibitor	2 (0.9)	1 (0.5)
Biguanide + Glinide	2 (0.9)	-
Biguanide + Sulfonylurea	28 (12.5)	24 (10.8)
Biguanide + Thiazolidinedione	4 (1.8)	4 (1.8)
Glinide + Sulfonylurea	1 (0.4)	-
Sulfonylurea + Thiazolidinedione	1 (0.4)	-
Receiving >2 OADs, n (%)	8 (3.6)	8 (3.6)
Alpha-glucosidase inhibitor + Biguanide + Sulfonylurea	3 (1.3)	5 (2.3)
Alpha-glucosidase inhibitor + Biguanide + Sulfonylurea + Thiazolidinedione	-	1 (0.5)
Biguanide + DPP-4 inhibitor + Sulfonylurea	1 (0.4)	-
Biguanide + DPP-4 inhibitor + Sulfonylurea + Thiazolidinedione	1 (0.4)	-
Biguanide + DPP-4 inhibitor + Thiazolidinedione	1 (0.4)	-
Biguanide + Sulphonylurea + Thiazolidinedione	2 (0.9)	2 (0.9)

OAD, oral antidiabetic drug. All data are n (%), unless otherwise specified.

## SUPPLEMENTARY DATA

**Supplementary Table 2.** Clinical interpretation of significantly different hypoglycemia rates during trial.

Type of event	To avoid 1 hypoglycemic episode you would need to treat*	If you treat 10 patients for 1 year with IDegAsp*
Confirmed	1 patient for 12 weeks	42.5 fewer episodes vs. BIAsp 30
Nocturnal confirmed	1 patient for 28 weeks	17.8 fewer episodes vs. BIAsp 30

\*These values were calculated based on the raw estimated rates in each arm.

**Supplementary Table 3.** Clinical interpretation of significantly different hypoglycemia rates during maintenance period (16 weeks to end of treatment).

Type of event	To avoid 1 hypoglycemic episode you would need to treat*	If you treat 10 patients for 1 year with IDegAsp*
Severe	1 patient for 3 years and 2 months (=163 weeks)	3.3 fewer episodes vs. BIAsp 30
Confirmed	1 patient for 9 weeks	56.9 fewer episodes vs. BIAsp 30
Nocturnal confirmed	1 patient for 23 weeks	23.0 fewer episodes vs. BIAsp 30

\*These values were calculated based on the raw estimated rates in each arm.

## Appendix

### BOOST®: Intensify Premix I All Trial Investigators.

Dr. Gregory Fulcher, Dr. Murray Gerstman, Prof. Robert Moses, Prof. Jonathan Shaw, Prof. J Wilson, Dr. Peder Bjerg Christensen, Dr. Klaus Levin, Dr. Sten Madsbad, Dr. Hans Perrild, Dr. Jens Sandahl Christiansen, Dr. Hanne Storm, Dr. Allan Vaag, Dr. Kari Askonen, Dr. Pirkko Korsoff, Dr. Jyrki Mäkelä, Prof. Leo Niskanen, Dr. Jorma Strand, Dr. Ganapathi Bantwal, Dr. Manoj Chadha, Dr. Hemraj B Chandalia, Dr. Sudip Chatterjee, Dr. Mathew John, Dr. Sanjay Kalra, Dr. Viswanathan Mohan, Dr. Vijay Viswanathan, Dr. Subhash.K. Wangnoo, Dr. Zanariah Hussein, Prof. Nor Azmi Kamaruddin, Prof. Wan Wan Bebakar, Dr. Tadeusz Dereziński, Dr. Roman Kuczerowski, Dr. Miroslawa Polaszewska-Muszynska, Dr. Elzbieta Poplawska, Dr. Małgorzata Wojciechowska, Dr. Peter Bosson, Dr. Peter Hallgren, Dr. Johan Jendle, Dr. Pekka Koskinen, Dr. Mona Landin-Olsson, Dr. Thomas Nyström, Dr. Chieh-Hsiang Lu, Dr. Wen-Ya Ma, Dr. Shih-Li Su, Prof. Chaicharn Deerochanawong, Prof. Natapong Kosachunhanun, Prof. Sompongse Suwanwalaikorn, Prof. Varaphon Vongthavaravat, Prof. Berrin Çetinarslan, Prof. Aytekin Oğuz, Prof. Haluk Sargin and Prof. Tufan Tükek